ABT-199 (Venetoclax)

Catalog No. A12500

ABT-199 is a so-called BH3-mimetic drug, which is designed to block the function of the protein Bcl 2.
  • Chauhan D, .et al. BAX/BAK-Induced Apoptosis Results in Caspase-8-Dependent IL-1β Maturation in Macrophages, Cell Rep, 2018, Nov 27;25(9):2354-2368.e5 PMID: 30485805
  • Martin Grundy, .et al. Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling, PLoS One, 2018, 13(1): e0190682 PMID: 29298347
  • Joanne Dai, .et al. Intracellular BH3 profiling reveals shifts in anti-apoptotic dependency in B-cell maturation and activation, J Immunol, 2018, 200 (5) 1727-1736 PMID: 29358277
Catalog Num A12500
M. Wt 868.44
Formula C45H50ClN7O7S
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 1257044-40-8
Synonyms ABT199; ABT 199; GDC-0199; RG7601
SMILES CC1(CCC(=C(C1)C2=CC=C(C=C2)Cl)CN3CCN(CC3)C4=CC(=C(C=C4)C(=O)NS(=O)(=O)C5=CC(=C(C=C5)NCC6CCOCC6)[N+](=O)[O-])OC7=CN=C8C(=C7)C=CN8)C
ABT-199 is a so-called BH3-mimetic drug, which is designed to block the function of the protein Bcl 2.
Targets
Bcl-2 (Cell-free assay) Bcl-xL (Cell-free assay) Bcl-w (Cell-free assay) Mcl-1 (Cell-free assay)
444 nM(Ki)
In vitro (25°C) DMSO 100 mg/mL (115.14 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% PEG400/0.5% Tween80/5% propylene glycol 20 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 11.51 mL 57.57 mL 115.15 mL
0.5 mM 2.3 mL 11.51 mL 23.03 mL
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL

*The above data is based on the productmolecular weight 868.44. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.